SCHEMBL4121879

SCHEMBL4121879

CN(NC(=O)c1c(C(F)(F)F)nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12)c1ccccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR3C1 P04150 1/20 0.34
POLB P06746 3/20 0.33
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33
CNR1 P21554 3/20 0.33
GPBAR1 Q8TDU6 2/20 0.33
KDM4E B2RXH2 1/20 0.32
PDE4B Q07343 1/20 0.32
ARF6 P62330 1/20 0.32
MAPT P10636 1/20 0.32
TACR1 P25103 2/20 0.32
TACR3 P29371 2/20 0.32
CNR2 P34972 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124736 0.86 CNR1 (0.34) HTTSMN1; SMN2NR3C1CNR1KDM4E
SCHEMBL4124748 0.85 CNR1 (0.34) SMN1; SMN2LMNACNR1MAPTTDP1
SCHEMBL2086773 0.85 F10 (0.34) SMN1; SMN2NR3C1CNR1MAPTMEN1
SCHEMBL2085682 0.85 CNR1 (0.33) SMN1; SMN2NR3C1LMNACNR1MAPT
SCHEMBL2085825 0.84 MAPT (0.32) SMN1; SMN2LMNACNR1MAPTCNR2
SCHEMBL4112770 0.84 NPC1 (0.33) SMN1; SMN2NR3C1LMNACNR1MAPT
SCHEMBL2085549 0.83 LMNA (0.36) NR3C1POLBLMNAGAAGPBAR1
SCHEMBL4121225 0.82 JAK2 (0.36) SMN1; SMN2POLBLMNAKDM4EPDE4B
SCHEMBL2084584 0.81 MALT1 (0.32) SMN1; SMN2CNR1MAPT
SCHEMBL2085649 0.81 NR3C1 (0.39) SMN1; SMN2NR3C1POLBCNR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US claimed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US claimed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD HTT 2012/4885SMN1; SMN2 3307/4885NR3C1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.